Efficient Major Histocompatibility Complex
Class II-restricted Presentation of Measles Virus Relies
on Hemagglutinin-mediated Targeting to Its Cellular
Receptor Human CD46 Expressed by Murine B Cells

By Denis Gerlier, Marie-Claude Trescol-Biémont,
Gayathri Varior-Krishnan, Denise Naniche, Isabelle Fugier-Vivier,
and Chantal Rabourdin-Combe

From the Laboratoire d’Immunobiologie Moléculaire, UMR 49, Centre National de la
Recherche Scientifique–Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 07, France

Summary
Measles virus after binding to its cell surface human CD46 receptor fuses with the plasma membrane.
This fusion results in envelope hemagglutinin (H) and fusion glycoprotein (F) incorporated into
the plasma membrane and injection of the nucleocapsid made of nucleoprotein (NP) into the
cytoplasm. The influence of targeting measles virus (MV) to CD46 in the processing and presentation
of MV H and NP to antigen-specific MHC class II-restricted T cell hybridomas was explored using murine M12-CD46 B cell transfectants. Parent M12 cells, which lack any
MV receptor, were unable to present any of these two viral proteins when incubated with MV
particles. Incubating M12.CD46 cells with 200 ng and 10 μg of MV could strongly stimulate
H-specific and NP-specific T cells, respectively. Neosynthesis of MV proteins was not necessary
since the efficiency of antigen presentation was similar when using ultraviolet-inactivated MV.
Similar enhancing effects (more than 1,000-fold) on antigen presentation were also observed when
using purified native H soluble or incorporated into liposomes whereas denaturating H glycoprotein
resulted in a poor efficiency in T cell stimulation, M12.CD46 being no more potent than the
parental M12 counterpart. MV H and NP presentation efficiency did not depend on MV fusion
with plasma membrane as revealed by the lack of effect of specific fusion inhibitors. Both MV
H and NP presentations were sensitive to chloroquine inhibition indicating that antigens from
CD46-mediated captured MV were likely processed in the endosome/lysosome compartment.
Altogether these data indicate that (a) MV targeting via CD46 has a strong effect on the efficiency
of antigen presentation by MHC class II, (b) the effect is mediated by the binding of H to CD46,
and (c) though MV does fuse with plasma membrane, endocytosis, and processing of virus particles
are also occurring. Since, in humans, CD46 is expressed in almost every tissue including professional
antigen-presenting cells, such a targeting is likely to play a crucial role in the CD4+ T
cell-mediated primary immune response against the pathogen in vivo.

Targeting a soluble exogenous antigen to antigen-specific
B cells via their cell surface Ig (1, 2) or to macrophages
via their FcR, after opsonization with specific antibodies (3)
result in a strong enhancement of MHC class II-restricted
antigen presentation to CD4+ T cells. Therefore, the specific
cellular receptor used by an intracellular pathogen to enter
hosts’ cells should play a crucial role in the induction of the
immune response by facilitating the pathogen capture by the
APC and the presentation of pathogen-derived antigens by
MHC class II molecules to specific T cells. We have recently
identified the human CD46 molecule (membrane cofactor
protein), a regulator of the complement activation (4), as a
receptor for measles virus (MV) (5, 6). MV is a pleomorphic,
enveloped and negative, single strand RNA virus belonging to
the Morbillivirus genus and Paramyxovirus family. The
envelope is made of two glycoproteins, hemagglutinin (H)
and fusion protein (F) responsible for MV attachment and
fusion with the plasma membrane of target cells. This fusion
results in H and F incorporation into the plasma membrane
and in the delivery into the cytosol of the nucleocapsids es-
sentially made of RNA and nucleoprotein (NP). Then viral
replication can occur. Thus, MV infection does not require
virus particle endocytosis and an acidic pH for fusion as is
the case for influenza virus. MV is the causative agent of the
measles disease in humans and can only infect human and
some simian cells. Expression of CD46 allows mouse M12
B cell transfectants (a) to bind MV, (b) to fuse to each other to form syncytium when both measles H and F glycoproteins are expressed after infection with MV or with recombinant vaccinia virus encoding H and F glycoproteins, and (c) to look for a receptor-mediated enhancement of MHC class II-restricted H and NP presentation when MV is targeted to CD46, (b) to test the ability of H to bind to CD46, and (c) to determine whether after CD46 targeting of MV, H, and/or NP antigen presentation by MHC class II involves an endosomal pathway although MV can fuse at the plasma membrane.

Materials and Methods

Measles Virus, Viral Proteins, and Antibodies. MV (Halle strain) was produced and purified as previously described (7). In some experiments, MV was UV-irradiated before use by 15 min exposure at 5 cm from a 254-nM UV-lamp. UV-treatment abolished transcription and replication of the viral genome without inhibiting its binding and fusion abilities. Native H glycoprotein was purified from Vero cells infected with MV and incorporated into liposomes as previously described (7). Denaturated H glycoprotein was purified under strong denaturing conditions in the presence of sodium dodecylsulfate and mercaptoethanol from insect cells infected with a recombinant baculovirus encoding H glycoprotein according to a procedure to be described elsewhere (Cretin F., I. Chrétien, I. Fugier-Vivier, D. Gerlier, and C. Rabourdin-Combe, in preparation). It differed from the purified native H by its lack of reactivity with conformational anti-H mAbs such as cl55 and it was no longer in dimeric form due to the use of reducing conditions during purification. A cytosolic extract of High-Five insect cells infected with a recombinant baculovirus encoding measles NP was used as a source of crude NP (BI-NP). High-Five insect cells were infected with 5 PFU/cell of recombinant AcNPV baculovirus obtained according to a published procedure (8). 3 d later, the cells were washed, pelleted, and disrupted in 1 mM EDTA, 0.5 mM Tris/HCl buffer, pH 7.5, supplemented with a cocktail of antiproteases for 0.5 h on ice. After centrifugation at 10,000 rpm for 1 h, the supernatant was kept frozen at -20°C until use. NP usually represents between 50 and 80% of the total protein present in the cell extract. For some experiments, NP was immunopurified after adsorption on a batch of anti-NP cl25 monoclonal antibody coupled to CNBr activated Sepharose 4B (Pharmacia, Uppsala, Sweden) and elution using 0.2 M HCl-glycine buffer, pH 2.5. The purity of the NP preparation was assessed after SDS-PAGE electrophoresis and silver staining. MV H-, NP-, and F-specific antibodies (cl55, cl25, and B22-F5, respectively) were kindly provided by T. F. Wild and P. Giraudon (Institut Pasteur de Lyon and Université de Lyon, France, respectively) (9, 10).

Cell Lines. M12.CD46 cells expressing human CD46 have been obtained after transfection with the pRV-CD46 expression vector of the mouse B lymphoma M12.4.1 cells (6). The H-specific and I-Eα-restricted T cell hybridoma TH5.124 has been previously described (11). The NP-specific and I-Aα-restricted TNP.408 T cell hybridoma was isolated using a procedure previously described (11).

T Cell Stimulation Assay. Antigen stimulation of the T cell hybridomas was performed by cocultivating 105 hybridoma cells with 3 × 104 H-2d M12.4.1 or M12.CD46 B cells in the presence or absence of serial dilutions of antigen in a final volume of 200 µl in 96-well microplates. In some experiments, M12.HELs3 cells that secrete hen egg lysozyme (11) were used instead of M12.4.1 cells. The secretion of lysozyme did not interfere with the bioassay. After incubation for 20 h at 37°C, IL-2 production in supernatants was measured using the MTT colorimetric CTL-L2 bioassay (11). All the experiments were repeated several times with similar results and the standard deviation between replicates was usually well below 5%. Some experiments were done in the presence of 50 µM chloroquine added to APCs before the antigen and maintained throughout the bioassay as described elsewhere (12). These chloroquine concentrations were well tolerated by the cells and did not affect the CTL-L2 bioassay (12). In other experiments, 10 µg of the z-Nphe-Phe-Gly and Gly-Phe-Phe tripeptides (Nsysèmes, Strasbourg, France) or cl55 anti-H and cl anti-F ascitis fluid in a final dilution of 1:50 were added during the T cell stimulation.

Results

Expression of CD46 by Murine APC Is Required for Efficient Presentation of Virus Proteins by MHC Class II Molecules. When incubated with infectious MV, M12.CD46 cells were very efficient in presenting H glycoprotein to the I-Eα-restricted TH5124, whereas M12 parent cells were unable to stimulate these T cells (Fig. 1 a). Incubating M12.CD46 cells with as few as 200 ng of virus was sufficient to stimulate TH5124 T cells. Viral replication and neosynthesis of H glycoprotein...
known to occur in M12.CD46 cells (6) were not necessary for efficient presentation because T cells were stimulated as efficiently when MV was UV-inactivated (Fig. 1 a). Efficient presentation was not limited to the viral envelope H glycoprotein since NP-specific and I-\(^{A^2}\)-restricted TNP.408 T cell hybridomas were stimulated in the presence of M12.CD46 but not M12 fed with UV-MV (Fig. 1 b). Allowing MV genome transcription and replication in M12.CD46 did not

result in further enhancement of NP presentation (data not shown). These results indicated that MV captured via CD46 provided an optimal amount of both virion H and NP proteins for antigen processing and presentation by MHC class II molecules. In an attempt to mimic such a capture effect, M12 cells that express FeR\(\gamma\) (13) were incubated with MV in the presence of anti-H or anti-F mAbs.

Indeed, the opsonization of MV particles by antibodies resulted in some presentation of both viral structural proteins H (Fig. 1 c) and NP (data not shown) by MHC class II molecules. The efficiency of antibody-mediated capture of MV was however far lower than the CD46 mediated capture (compare Fig. 1 a and c) in agreement with the poor internalization of the FeR\(\gamma\)1Ib1 receptor isoform expressed in B cells (14).

***CD46 Mediates Efficient Presentation of Purified Native But Not Denatured H Glycoprotein.*** The MV H envelope glycoprotein has long been thought to be the binding structure used by MV to attach to its target cells. To verify that MV H can directly bind to CD46, the efficiency of M12.CD46 to present purified native H glycoprotein to TH5.124 T cells was tested. Indeed, M12.CD46 requires ~100-fold less purified soluble H than its parental M12 counterpart to stimulate TH5.124 T cells was tested. Indeed, M12.CD46 requires ~100-fold less purified soluble H than its parental M12 counterpart to stimulate TH5.124 T cells with the same efficiency (Fig. 2 a). The difference was even higher when purified H were given to the APC as liposomes (Fig. 2 b). This was due both to the higher efficiency of M12.CD46 cells and to the poor ability of M12 cells to present H in a particulate form as observed with MV particles. M12.CD46 was so efficient at capturing H-liposomes that as little as 10 ng/ml of H glycoprotein (i.e., an H concentration around 0.06 pM since the Mr of H homodimer is \(\approx\)160) was sufficient to give a strong stimulatory signal to TH5.124 T cells. This antigen presentation efficiency was comparable to the high efficiency of endogenous H presentation by M12.H transfectants (data not shown and II). This was >100 times less than the amount of purified native H required by parental M12 cells to stimulate these T cells with the same efficiency (compare Fig. 2 a and b). In contrast, M12.CD46 and M12 cells were equally (and rel-
Class II Presentation of Measles Virus Targeted to CD46

Efficient Presentation of MV Antigens Targeted to CD46 Does Not Require MV Fusion at the Cell Membrane but Involves a Chloroquine Sensitive Pathway. For cell infection, MV enters its target by fusing with the plasma cell membrane and does not require endocytosis. This fusion process involves both H and F glycoproteins, F glycoprotein having the fusogenic properties (6, 15). To test the role of the fusion, anti-F mAbs (10) and the tripeptide z-D-Phe-Phe-Gly (16) were used as specific fusion inhibitors. Whereas both anti-F antibodies and z-D-Phe-Phe-Gly tripeptide completely abrogated the H + F induced cell–cell and MV–cell fusion (data not shown) they left intact the efficiency of MV H and NP presentation by M12.CD46 to TH5.124 and TNP.408 T cell hybridomas (Fig. 3). The tripeptide Gly-Phe-Phe, which has no effect on MV-induced fusion, was used as a negative control. The lack of inhibition by the anti-F antibody could have been compensated for by the opsonizing effect and targeting to the M12 FeRγ. This is unlikely, since the efficiency of MV capture in the presence of anti-F is very limited (see Fig. 1 c). Surprisingly, when anti-H antibodies were used as a control, they were found to significantly decrease the efficiency of MV H presentation but not that of MV NP presentation (Fig. 3, a and c). This suggests that anti-H antibodies could specifically protect H glycoproteins from proteolytic degradation as previously observed by others (17).

Endosomal processing is inhibited by lysosomotropic agents, and the effect of chloroquine on the ability of M12.CD46 cells to present MV H and NP proteins was then tested. Presentations of H and NP from MV particles to TH5.124 and TNP.408 T cells, respectively, were almost completely abolished in the presence of 50 μM of chloroquine (Fig. 4). Similar results were obtained when using soluble NP, purified H in liposomes, or antibody-opsonized MV targeted to FeRγ of M12 cells (data not shown).

Discussion

By comparing mouse B cells devoid of cell surface expression of MV receptor with their counterparts expressing the human CD46, it is shown that targeting the virus to the APC via its cellular receptor dramatically increases (>1,000-fold) the efficiency of viral antigen presentation by MHC class II molecules. This effect is due to the efficient uptake of virus particle following the interaction of the viral envelope H glycoprotein and CD46 molecules as firstly reported here. It does not depend on the presentation of neosynthesized viral proteins since the UV-inactuation of MV did not change the efficiency of antigen presentation to CD44+ T cells.

The coexpression of MV H, MV F, and CD46 glycoproteins is sufficient to induce fusion between two cell membranes leading to the formation of syncitia (6). This fusion process is likely to be similar to the fusion between MV envelope and cell membrane allowing the MV nucleocapsids to enter the cytosol where viral replication occurs (6). This raises the possibility that MV fusion at the cell surface of M12.CD46 might be involved in the efficiency of MV antigen presentation. All the experimental data that have been obtained so far argue against this hypothesis. (d) Potent and specific inhibitors of MV H- and F-mediated fusion after binding to CD46 virus receptor such as anti-F antibodies (10) and z-D-Phe-Phe-Gly tripeptide which is homologous to the hydrophobic NH2 terminus of the F1 subunit of F glycoprotein (16) has no effect whatsoever on the ability of M12.CD46 cells to present MV proteins. (b) The CD46-mediated enhancing effect on MV antigen presentation was observed using purified soluble native H glycoprotein or H liposomes that, as shown previously (7), do not contain any detectable F glycoprotein strictly required for the fusion. Moreover, the chloroquine sensitivity of MV H and MV NP antigen presentation strongly suggests that the processing of these viral structural antigens occurs in an acidic endosomal/lysosomal compartment after receptor-mediated endocytosis of some MV particles although MV can fuse with plasma membrane. So, CD46-mediated enhancement of MV antigen presentation is likely to involve an endosomal processing pathway as observed for antigen targeted to a plasma membrane protein such as cell surface Ig of specific B cells or FeR of macrophages (1–3, 14, 17).

Comparison between soluble native H and H liposomes shows that the latter was more efficient in delivering H antigen for processing by M12.CD46 cells. A likely explanation is that the liposome vector allows the capture by a single APC of several H glycoproteins contained in one vesicle as soon as a single or few H glycoproteins have bound to CD46 molecules. This may partly explain the strong enhancing effect of liposome vector on the immunogenicity of a cell surface murine retrovirus glycoprotein previously reported by one of us (18). It has been previously reported that, in vitro, macrophages but not B cells can mediate presentation of (untar-
We hypothesize that, in vivo, efficient priming of CD4+ T cell–mediated immune response could mainly rely on peptides derived from exogenous antigens targeted to the APC (1–3, 14, 17, this paper) and/or endogenous antigens synthesized and translocated into the endoplasmic reticulum within the APC (11). Human CD46 is expressed on every cell type except on erythrocytes (4, 6). Thus, human CD46+ dendritic cells and macrophages that are likely to be the main APC involved in the in vivo primary stimulation of MHC class II–restricted CD4+ T cells should be able to capture efficiently MV leading to a strong primary immune stimulation even if the amount of virus and/or its infectivity is limited.

The authors are indebted R. Drillien and A. Devauchelle for providing antibodies, plasmids, and baculovirus. I. Chretien for the MV H recombinant baculovirus, and C. Gimenez, K. Belorizky, J. Marvel, and B. Horvat for helpful discussions and comments.

This work was supported in part by grants from the Institut National de la Sante et de la Recherche Medecine (C. Rabourdin-Combe 920611), Association pour la Recherche contre le Cancer (D. Gerlier, 6302; C. Rabourdin-Combe, 6108), and Ministère de l’Education Nationale et des Sciences (C. Rabourdin-Combe). This research project received financial support from the World Health Organization/UNPP Programme for Vaccine Development (PVD). G. Varior-Krishnan was supported by the Fondation Mérieux.

Address correspondence to Denis Gerlier, CNRS-ENS Lyon, UMR 49, 46 Allée d’Italie, 69364 Lyon CEDEX 07, France.

Received for publication 2 August 1993 and in revised form 8 October 1993.

References

1. Chestnut, R., and H.M. Grey. 1981. Studies on the capacity of B cells to serve as antigen presenting cells. J. Immunol. 126:1075.

2. Lanzavecchia, A. 1985. Antigen-specific interactions between T and B cells. Nature (Lond.). 314:537.

3. Cohen, B.E., A.S. Rosenthal, and W.E. Paul. 1973. Antigen-macrophage interaction. II. Relative roles of cytophilic antibodies and other membrane sites. J. Immunol. 111:820.

4. Liszewska, M.K., T.W. Post, and J.P. Atkinson. 1991. Membrane cofactor Protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9:431.

5. Naniche, D., T.F. Wild, C. Rabourdin-Combe, and D. Gerlier. 1992. A monoclonal antibody recognizes a human cell surface glycoprotein involved in measles virus binding. J. Gen. Virol. 73:2617.

6. Naniche, D., G. Varior-Krishnan, F. Cervoni, T.F. Wild, B. Rossi, C. Rabourdin-Combe, and D. Gerlier. 1993. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67:6025.

7. Gerlier, D., F. Garnier, and F. Forquet. 1988. Haemagglutinin of measles virus: purification and storage with preservation of biological and immunological properties. J. Gen. Virol. 69:2061.

8. Miller, L.K., D. Miller, and M. Adang. 1983. An insect virus for genetic engineering: developing baculovirus polyhedrin substitution vectors. In Genetic Engineering in Eukaryocytes. P. Lunquin, and A. Kleinhofs, editors. Plenum, New York, NY. 89–97.

9. Giraudon, P., and T.F. Wild. 1985. Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity. Virology. 144:46.

10. Malvoisin, E., and T.F. Wild. 1990. Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J. Virol. 64:5160.

11. Calin-Laurens, V., F. Forquet, S. Lombard-Platet, P. Bertolino, L. Chretien, M.-C. Trescol-Biémont, D. Gerlier, and C. Rabourdin-Combe. 1992. High efficiency of endogenous antigen presentation by MHC class II molecules. Int. Immunol. 4:1113.

12. Lombard-Platet, S., P. Bertolino, H. Deng, D. Gerlier, and C. Rabourdin-Combe. 1993. Inhibition by chloroquine of the class II MHC restricted presentation of endogenous antigens varies according to the cellular origin of the APC, the nature of the T cell epitope, and the responding T cell. Immunology. In press.

13. Kim, K.J., C. Kanellopoulos-Langevin, R.M. Merwin, D.H. Sachs, and R. Asofsky. 1979. Establishment and characterization of BALB/C lymphoma cell lines with B cell properties. J. Immunol. 122:549.

14. Amigorena, S., J. Salamero, J. Davoust, W.H. Fridman, and C. Bonnerot. 1992. Tyrosine-containing motif that transduces cell activation signals also determines internalization and an-
tigen presentation via type III receptors for IgG. *Nature (Lond.)* 358:337.
15. Wild, T.F., E. Malvoisin, and R. Buckland. 1991. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. *J. Gen. Virol.* 72:439.
16. Richardson, C.D., A. Scheid, and P.W. Choppin. 1980. Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides. *Virology.* 105:205.
17. Davidson, H.W., and C. Watts. 1989. Epitope-directed processing of specific antigen by B lymphocytes. *J. Cell Biol.* 109:85.
18. Gerlier, D., O. Bakouche, and J.F. Doré. 1983. Liposomes as a tool to study the role of membrane presentation in the immunogenicity of a MuLV related tumor antigen. *J. Immunol.* 131:485.
19. Dal Monte, P.R., and F.C.J. Szoka. 1989. Effect of liposome encapsulation on antigen presentation in vitro. Comparison of presentation by peritoneal macrophages and B cell tumors. *J. Immunol.* 142:1437.
20. Harding, C.V., D.S. Collins, O. Kanagawa, and E.R. Unanue. 1991. Liposome-encapsulated antigens engender lysosomal processing for MHC class II presentation and cytosolic processing for class I presentation. *J. Immunol.* 147:2860.
21. Grivel, J.-C., K. Crook, and L. Leserman. 1993. Endocytosis and presentation of liposome-associated antigens by B cells. *J. Immunol. Methods.* In press.